Allergan’s JUVÉDERM VOLBELLA XC approved by FDA

23 Jun 2016

The US Food and Drug Administration (FDA) has approved Allergan to market JUVÉDERM VOLBELLA XC for lip augmentation and to correct perioral rhytides in adults over the age of 21.

In several clinical trials including the US pivotal study where 168 subjects were treated with the dermal filler, the product was found to effectively increase lip fullness and soften the appearance of lines around the mouth in approximately two-thirds of patients treated through one year.

“JUVÉDERM VOLBELLA XC is formulated with VYCROSS, a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns such as lip fullness, age-related volume loss in the cheek area, or perioral rhytids," said Allergan chief commercial officer Bill Meury.

He continued, "The FDA approval of JUVÉDERM VOLBELLA XC further demonstrates Allergan's commitment to developing advanced products and technologies that allow healthcare providers to better address evolving patient needs." 


Log-in to post a comment